Search Results
Showing Results for anti-vascular endothelial growth factor therapy
Breast carcinoma is the most common cancer in females. An estimated 2.3 million new cases of breast carcinoma are diagnosed annually worldwide.1 These patients have potential risks of ocular complications not only from the secondaries in the eye but also due ...
On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov ...
The uvea is a vascular stratum that includes the iris, ciliary body and choroid. Uveitis is defined as inflammation of a part of the uvea or its entirety, but it is also used to describe inflammatory processes of any part ...
We are pleased to present the latest edition of touchREVIEWS in Ophthalmology. In this issue, we offer a series of engaging editorials, in-depth review articles and insightful original research highlighting some of the latest breakthroughs, innovations and practical insights in ...
Age-related macular degeneration (AMD) is a chronic deterioration and dysfunction of the outer retinal tissue and Bruch’s membrane (BrM). It is the leading cause of vision loss in people older than 60 years and is estimated to affect 288 million people ...
Retinal pharmacotherapy encompasses various drug delivery routes that offer potential avenues for effective treatment (Figure 1). Among these, intravitreal injections have emerged as the predominant method employed in clinical practice.1 They have established themselves as the primary approach for administering anti-vascular ...
The term ‘artificial intelligence’ was coined by a group of scientists during a workshop known as the “Dartmouth Summer Research Project on Artificial Intelligence” in 1956.1 The concept was based on the idea that “intelligent human behavior consisted in processes that ...
Neovascular age-related macular degeneration (nAMD) is an advanced form of macular degeneration that historically has accounted for the majority of vision loss related to AMD. Current treatment consists of injecting inhibitors of vascular endothelial growth factor (VEGF) into the vitreous ...
With the introduction of monoclonal antibody inhibitors for all isoforms of vascular endothelial growth factor (VEGF)-A, which were first presented in September 2005 with off-label use of bevacizumab, significant anatomical and visual improvements for neovascular age-related macular degeneration (nAMD) became ...
Identifying treatments that prevent diabetic retinopathy progression is a priority in current research. Patients with non-proliferative retinopathy currently have limited treatment options to prevent the progression of retinopathy and loss of vision, and therapies such as anti-vascular endothelial growth factor (...
Corticosteroids are the best choice for treating various ocular conditions affecting the anterior and posterior segments of the eye.1 Currently, different routes are available for ocular administration of corticosteroids. Topical application to the eye is the route of choice when ...
Welcome to the winter edition of touchREVIEWS in Ophthalmology, which features relevant topics from across the specialty. This edition contains a wide range of articles evaluating current practice and research, as well as innovations that directly affect ophthalmologists. The surgical ...
Biologics have redefined the outcomes of retinal pathologies by targeting the vascular endothelial growth factor (VEGF) pathway. Anti-VEGF therapy has prevented millions of people from going blind due to retinal vascular pathologies.1 Apart from preventing morbidity, it has a widespread ...
The subspecialty of the retina has been transformed by anti-vascular endothelial growth factor (anti-VEGF) medications over the last two decades.1 These include bevacizumab (Avastin®, Genetech, San Francisco, CA, USA), ranibizumab (Lucentis®, Genentech, San Francisco, CA, USA), aflibercept (Eylea®, Regeneron Pharmaceuticals, ...
Dr Rahul Khurana (Northern California Retina Vitreous Associates, Mountain View, CA, USA) took part in a retrospective cohort study investigating the incidence of loss to follow-up after anti–vascular endothelial growth factor (VEGF) injections among patients with neovascular age-related macular ...
Neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) associated with macular oedema are some of the leading causes of visual impairment and loss worldwide.1–3 The pathogenesis of these diseases is largely driven by the ...
Neurotrophic keratitis (NK), also referred to as neurotrophic keratopathy, is a rare disease characterized by trigeminal nerve dysfunction, leading to a reduction or loss of corneal sensation and subsequent degenerative changes in the cornea.1 Deterioration starts when spontaneous breakdown of ...
Age-related macular degeneration (AMD) is a leading cause of vision impairment and legal blindness in developed countries, with a projected estimate of 288 million cases in 2040.1 AMD can be classified as exudative or non-exudative. The early AMD-related lesion is represented by ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
